Purpose: Radial artery occlusion flowing cardiac catheterisation has been linked to flow reduction and prolonged compression. We investigate whether these factors can be optimised following transradial cardiac catheterisation by using an accelerated band removal protocol facilitated by a haemostasis promoting pad, in combination with a patent haemostasis technique.
INTRODUCTION
Use of transradial access (TRA) for cardiac catheterization procedures is increasing worldwide. 1, 2 TRA offers significant patient benefits over transfemoral access (TFA) with fewer access site complications, improved patient comfort, reduced costs and a reduction in MACE in high risk groups. [3] [4] [5] [6] [7] [8] In view of this, the most recent European Society of Cardiology guidelines for management of non-ST elevation myocardial infarction (NSTEMI), recommend TRA with a class 1A indication, for invasive management of NSTEMI with PCI. 9 However, the transradial approach is still not free from access site complications although they are low in comparison to TFA. 6, 7, [10] [11] [12] In comparison to the femoral artery, the radial artery is small, superficial and easily compressible. This facilitates haemostasis following procedures and the use of dedicated haemostasis devices allows for almost immediate ambulation of patients, reducing post procedure nursing input. [13] [14] [15] Since the introduction of TRA, there have been many advances to achieve optimal haemostasis, predominantly in an effort to minimise complications, improve patient comfort and reduce radial artery occlusion (RAO). 16, 17 Optimising haemostasis with gentler, less prolonged and patent haemostasis has been shown to be associated with lower rates of RAO. 10, 18 A reduction in haemostasis time following TRA procedures potentially lessens amount of nursing input required, facilitates early discharge, reduces overall costs and has the potential to reduce radial artery occlusion rate. 14 Materials to promote haemostasis have previously been used to facilitate removal of venous and dialysis lines. 13 At our high volume radial centre we sought to evaluate a new accelerated haemostasis protocol (AHP) using our standard haemostasis compression device, the Helix TM ( Figure 1A ) with the addition of a haemostasis promoting disc ( Figure 1B ) in combination with a standard patent haemostasis technique.
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METHODS
STUDY POPULATION AND RECRUITMENT
This study was a prospective, single-centre, open-label, randomized controlled trial to evaluate two haemostasis protocols following TRA coronary procedures. All patients presenting to our institution between May and November 2017 for coronary procedures irrespective of the indication were enrolled. Patients were excluded if radial access was not used, or if they were planned to be transferred to other hospitals after completion of procedure before the compression device had been removed. Patients were randomised to either an accelerated haemostasis protocol with a haemostasis promoting disc (AC group), or standard compression with Helix alone (HC group). The haemostasis promoting material is a 14mm diameter disc (StatSeal® Advanced), comprised of a hydrophilic polymer that dehydrates blood and potassium ferrate, a compound that agglomerates blood solids to create a seal without interfering with the normal haematological clotting process.
PROCEDURAL DETAILS
All procedures were carried out as standard using 5F or 6F radial sheaths (Terumo, Glidesheath Slender). All patients received heparin (at least 5000 iu for diagnostic procedures and 70-100 iu/kg for interventional procedures according to operator preference). In both groups following completion of the cardiac procedure the vascular sheath was removed in the catheterisation laboratory and compression applied with the helix device until no visible bleeding was apparent.
Following sheath removal patients were immediately ambulated and transferred to the recovery area. An oximeter was placed on the patients index finger, transient ulnar compression was applied to the patients ulnar artery, and patent haemostsis was achieved by reducing helix compression until an oximeter signal reappeared ( Figure 2 ). In the HC group, compression time protocol was 60 minutes per 2500 iu of heparin administered. In
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the AC group, we used our in-house AHP (Table 1) with the aim of achieving haemostasis within 60 minutes, irrespective of heparin dose.
Before applying the StatSeal® Advanced disc, the radial sheath is withdrawn 1-2 centimetres allowing space for the disc to be placed directly over the puncture site. This is then covered with a transparent adherent dressing before the Helix TM compression device is applied on top of disc. The sheath is then withdrawn while tightening the helix band ( Figure 3 ). In both groups, after the allocated compression time had elapsed, pressure in the Helix TM was completely released. Following this, the Helix TM is then removed and the access site is assessed for any re-bleeding or haematoma. In the event of any re-bleeding the Helix TM was reapplied for a further 20 minutes before attempting the removal protocol again. In the AC group, the transparent dressing (with StatSeal® Advanced Disc underneath) was left in-situ and patients were advised to remove this after 24 hours.
STUDY ENDPOINTS
The primary (efficacy) endpoint was time to haemostasis defined as the total time elapsed from removal of the sheath to removal of the compression device with achievement of satisfactory haemostasis. Secondary (safety) endpoints were the incidence of (i) re-bleeding defined as any visible bleeding from the access site after initial removal of the compression device that necessitated re-application of the compression device, (ii) haematomas classified according to the Early Discharge After Transradial Stenting of Coronary Arteries (EASY) haematoma grading 19 and (iii) radial artery patency checked within 24 hours following removal of the compression device using a reverse Barbeau's Test. 20
STATISTICAL ANALYSIS
Normality was assessed using the Shapiro-Wilk test, histograms and Q-Q plots. Normally distributed data are shown as mean ± SD and non-parametric data as median (25-75% quartiles). Differences between the study groups were assessed using independent t-test (for continuous data) or chi-squared test (for categorical data). Statistical analysis was performed using Statistical Package for Social Sciences, SPSS v22.0 (Chicago, IL, USA). A pvalue of <0.05 was considered statistically significant.
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RESULTS
POPULATION CHARACTERISTICS
We enrolled 389 patients (191 randomised to HC and 198 patients to AC) between May and November 2017. Patient characteristics are listed in Table 2 . Our study population had a mean age of 66, with a male: female ratio of approximately 3:1. Baseline characteristics were similar in both groups apart from a higher proportion of coronary intervention in HC group (55% vs 42.4%, P=0.013). Importantly, there was no significant difference in dose of heparin in the groups. Over 92% of participants in both groups had their procedure performed using a 6 Fr sheath.
TIME TO HAEMOSTASIS (PRIMARY OUTCOME)
The primary end point of time to haemostasis was significantly lower in the AC group at 79.7 
SECONDARY SAFETY OUTCOMES
There was no significant difference in re-bleeding between the HC and AC groups (3.7% vs 5.6%, p=0.37) but the incidence of EASY grade I/II haematoma was more frequent in the AC group (4.7% vs. 12.1%, p=0.009). No patients had a haematoma larger than grade II. The rate of RAO was lower in the AC group but this difference did not reach statistical significance (6.3% vs 4.1%, p=0.33)
DISCUSSION
In this randomized control trial, we evaluated the efficacy of an accelerated haemostatic protocol (AHP) in conjunction with the StatSeal Advanced® haemostatic disc. Using an AHP, reduced the haemostasis time to half that of our conventional haemostasis protocol.
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Moreover, this reduction was achieved without a significant increase in vascular complications such as re-bleeding and RAO. This is in-keeping with previous studies of haemostatic adjuncts following percutaneous vascular interventions. 21 In our study, the AC group had a higher incidence of haematoma but an equivalent rate of re-bleeding. This may be related to the reduced compression time not allowing for adequate haemostasis as has been observed in other studies with very low compression times 20, 22 .
Additionally the use of a 14mm round disc shaped Statseal may have reduced bleeding at the skin puncture but led to less effective haemostasis at the arterial puncture site. The small diameter of the disc may have led to uneven compression over the puncture site with most of the pressure over the skin puncture and less over the deeper, more proximal arterial puncture. The development of a rectangular shaped Statseal that allows for more even compression over a wider area may be further evaluated in the future, but was not available at the time of our study. All the haematomas observed in our participants were small (EASY grade II or less) and did not require any intervention. The rate of re-bleeding was the same in both groups and was successfully managed in all patients by reapplying compression.
The rate of RAO was the 35% higher in the HC group. Although this did not achieve statistical significance this may be due to a lack of power in our study. This observation requires further study as a reduction in RAO is an important objective. RAO has been observed in 1-30% of procedures and reduces options for repeat procedures, haemodialysis fistulae and coronary bypass grafting. Interventional operators employ a number of measures to prevent RAO, including minimising sheath size, utilising patent haemostasis, minimising access-site compression time and using adequate anticoagulation and vasodilator therapies. 9, 24, 25 At our high volume, transradial centre, we routinely employ all
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these strategies and this may account for the low overall incidence of RAO seen in our study, despite assessing RAO at a time-point when this is often more frequent. [26] [27] [28] Additionally, the numerically lower rate of RAO observed in the AC group is reassuring as haematoma is often associated with higher rates of RAO due to more prolonged and occlusive pressure, often applied in response to the development of a haematoma.
In our study, we noted a significant reduction in compression time with the AHP and Statseal advance. This is not only important in terms of patient comfort and convenience, but also promotes early ambulation and increases patient satisfaction. 20, 22 . Additionally, the decreased requirement for nursing input may contribute to the reduced costs when TRA is compared to TFA for coronary procedures 29 . Importantly same day discharge is more likely when TRA is used, leading to markedly reduced costs compared to TFA, not only because of fewer complications but because of less utilisation of hospital resources. [29] [30] [31] [32] [33] [34] Patients are often still advised to be monitored for at least 4 hours post coronary intervention, 19, [35] [36] [37] [38] however, optimisation of post procedure care with the use of dedicated radial lounges has improved efficiency and patient satisfaction. 39 The use of AHPs may add further benefit in facilitating early ambulation and discharge.
Other recent studies have investigated patent haemostasis and AHPs with various types of adjunctive haemostasis devices including a chitosan-based pad 40 and QuikClot. 41 They have also demonstrated decreased haemostasis times, however in these studies allergic reactions to the materials in the devices were observed. Interestingly, no such adverse immunological reactions were observed with the StatSeal Advanced® disc in our study. The StatSeal
Advanced® haemostatic disc therefore appears to be a safe adjunct to achieving patent haemostasis with an AHP by allowing substantial reduction in compression time, which may lead to reduced nursing time and hospital costs.
LIMITATIONS
This trial was conducted at a single centre with considerable radial expertise and hence our findings may not be generalizable to other centres with less TRA expertise, or in centres where an alternative compression device is used. Our study is also limited by a small sample
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size which limits the ability to interpret the results for study end points with low incidence such as radial artery occlusion and therefore a larger multi-centre randomised trial is required to corroborate our findings. Evaluation of radial artery patency in our study did not include ultrasound assessment, which may be more robust. Furthermore, radial artery patency is highly associated with the duration of haemostatic compression and although we report that the StatSeal Advanced® disc facilitates safe reduction of the haemostatic time, we did not include a third study arm comprising of the AHP alone. Finally, patients were not followed up to assess radial artery patency after a longer time period but it would be expected that the rate of RAO would decrease with time, as has been demonstrated in multiple studies. 10, 16, 18, 26, 27 
CONCLUSIONS
Use of an AHP is feasible and reduces compression time. More rapid haemostasis can be achieved with use of an AHP and the StatSeal® disc without conferring significant additional complications following TRA. The Statseal Advanced® disc is a safe and effective adjunct to compression devices and may allow earlier mobilisation and reduce nursing input following TRA procedures. The effects on radial artery patency warrant further investigation in larger trials.
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COMPETING INTERESTS
None.  There were no significant differences in re-bleeding and RAO between groups (3.7% versus 5.6%, p=0.37 and 6.3% versus 4.1%, p=0.33) respectively. Incidence of haematoma was higher in accelerated compression group (4.7% versus 12.1%, p=0.009).
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